Innovation to trigger the Injectable Drug Delivery Market

Published On : 11/22/2021

The Injectable Drug Delivery Market ought to witness an explicit In Upcoming Years. With geographical barriers out of sight, track-and-trace programs are on the verge to reach their zenith in the timespan mentioned above. This could be credited to OEMs trying to reach out to the end-users remotely through virtual setups. Plus, people are getting a broader choice regarding choosing the experts. This holds for preventive as well as curative measures. The trend is certain to embark upon massive transience in the years to come.

The Injectable Drug Delivery Market is expected to reach US$ 30.5 Billion at a CAGR of 9% from 2019 to 2029. Tech-driven innovation is the trend that the healthcare vertical would be resting on in the forecast period. With precision medicine being the focal point, extensive research is being carried out in every arm of the healthcare vertical. The status quo is expected to stay unchanged even in the forecast period.

Over the years, there has been a rise in the demand for convenient and efficient drug delivery systems for patients that rely on prescription drugs on a regular basis.

This creates a lucrative opportunity for pharmaceutical manufacturers all over the world to develop sophisticated, easy-to-use, and effective injectable drug delivery devices. Moreover, rise in the prevalence of chronic diseases such as diabetes, cancer, and rheumatoid arthritis are likely to fuel the growth of the injectable drug delivery market style=”font-weight: 400;”> during the forecast period.

• Eli Lilly and Company
• Biocon
• Becton, Dickinson & Company
• West Pharmaceutical Services, Inc.
• Johnson & Johnson
• Antares Pharma
• AbbVie Inc.
• Pfizer Inc.
• Mylan N.V.
• Vetter Pharma-Fertigung GmbH & Co.KG
• Emperra GmbH
• Digital Medics Pty Ltd
• Enable Injections LLC
• Insulet corporation
• Consort Medical Plc
• Diabnext
• Diamesco Co., Ltd
• SCHOTT AG
• SiO2 Medical Products
• Integrity Bio, Inc.
• Wilhelm Haselmeier GmbH & Co. KG
• Tandem Diabetes Care
• Sanofi S.A.
• Companion Medical Inc.
• Ypsomed
• Hoffman – La Roche Ltd.
• Novo Nordisk A/S
• Medtronic Plc.

The global injectable drug delivery market was valued at US$ 30.5 Bn in 2018, and is expected to exhibit a CAGR of around 9% during the forecast period (2019–2029).

Get A Customized Scope To Match Your Need Ask An Expert – sales@persistencemarketresearch.com

Key Takeaways of Injectable Drug Delivery Market Study

• Insulin pens contributed the most share to the injectable drug delivery market in 2018, due to the rising prevalence of diabetes in developing countries.
• Non-smart injector technology accounted for a prominent share in the global injectable drug delivery market in 2018, due to increase in the adoption of advanced technology and rising demand for smartphone-integrated products.
• Rise in the demand for connected devices and the high cost of such devices offer growth opportunities for manufacturers of reusable injectable drug delivery devices.
• Diabetes indication is expected to continue to hold a prominent position in the injectable drug delivery market throughout the forecast period.
• Increase in the number of pharmaceutical manufacturers has contributed to the dominance of North America in the global injectable drug delivery market.
• Attributed to growing awareness regarding various diseases such as cancer and diabetes, East Asia is expected to register notable growth opportunities for the injectable drug delivery market.

Starting With The New Decade On A Diligent Note In The Injectable Drug Delivery Market? https://www.persistencemarketresearch.co/methodology/3774

“Smart injectable drug delivery devices not only improve patient compliance to treatment but also collect extensive data that is valuable for future research. Rising demand for connected injectable drug delivery devices will offer significant growth opportunity for the injectable drug delivery market,” says a PMR analyst.

Trends in Smart Injectable Drug Delivery Technologies

There are many research and pipeline products that will have the ability to connect with smartphones and trackers. However, current smart products are predominantly available as reusable devices.

This is attributed to the current state of technology that requires further advancements to apply to disposable products. According to a number of studies and key opinion leaders in the industry, there are a number of factors that limit disposable injectable drug delivery devices from being integrated with smart/connecting technologies.

Some of these factors include high cost of Bluetooth integration, low range connectivity with NFC, and lack of power source for connectivity. Thus, although disposable injectable drug delivery will continue holding a larger share throughout the forecast period, reusable injectable drug delivery devices have the potential to grow at a relatively faster rate, at least in the first five years of the forecast period.

How About Obtaining Insights About The Region To Enter Concerning The Injectable Drug Delivery Market? Press The “Purchase Now” Button To Have Our Injectable Drug Delivery Market Report! https://www.persistencemarketresearch.com/checkout/3774

More Valuable Insights on Injectable Drug Delivery Market

Persistence Market Research offers a unique perspective and actionable insights on the injectable drug delivery market in its latest study.

The report presents historical demand assessment of 2014–2018 and projections for 2019–2029, on the basis of product (self-injectors, needle-free injectors, auto injectors, wearable injectors, and insulin pens), technology (non-smart injectors and smart injectors), usage (disposable injectors and reusable injectors), indication (anaphylaxis, diabetes, cardiovascular diseases, multiple sclerosis, rheumatoid arthritis, cancer, trauma and emergency, and others), and distribution channel (hospital pharmacies, drug stores, retail pharmacies, and online pharmacies), across seven regions.

About us: Persistence Market Research

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

Uma Rajagopal

Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.